Story
HUTCHMED Shares Soar on $1.3 Billion Cancer Drug Licensing Deal with GSK
Shares of HUTCHMED (HCM) surged more than 14% in morning trading after the biopharmaceutical company announced an exclusive global licensing agreement with a subsidiary of GSK plc for its novel cancer drug candidate, HMPL-A830. The deal carries a total potential value of up to $1.295 billion.
Deal Details
Under the terms of the agreement, HUTCHMED will receive an immediate upfront payment of $110 million. The company is also eligible for up to $1.185 billion in additional payments contingent on achieving specific development, regulatory, and commercial milestones.
The agreement also includes tiered royalties on net sales. GSK gains exclusive worldwide rights to develop and commercialize HMPL-A830, except in Mainland China, Hong Kong, Macau, and Taiwan, where HUTCHMED will retain all rights.
Strategic Significance
The deal provides significant validation for HUTCHMED's proprietary antibody-targeted therapy conjugate (ATTC) platform. HMPL-A830 is a first-in-class therapy candidate that combines a monoclonal antibody with a small-molecule inhibitor to target KRAS-EGFR pathways in cancer cells.
AdActing CEO Johnny Cheng called the agreement a "significant step" in maximizing the drug's potential and noted it was the first global licensing transaction from the company's ATTC platform. Initial clinical development will focus on colorectal, pancreatic, and lung cancers, with a global Phase I study expected to begin in the second half of 2026, according to the announcement.
Market Reaction
The stock's sharp rise was a direct reaction to the high-value partnership with a major pharmaceutical firm. Investor interest was further amplified by a business update webcast hosted by the company.
Analysts also noted a secondary tailwind from the recent conditional approval in China for another of the company's drugs, fanregratinib, for a type of bile duct cancer. While the broader market saw modest gains, HUTCHMED's performance was overwhelmingly driven by these company-specific developments.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.
Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.
Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.
DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.